9.4. tissue engineered grafts. 9.4.1. cell-free tissue engineered grafts grafts derived cadaveric animal sources (e.g., porcine small intestine submucosa [sis], acellular bladder matrix, acellular dermal matrix), completely cell-free serve scaffold host cell ingrowth . main advantage suggested use off-shelf availability . small rct (n=30) comparing acellular bladder matrix bmg reported urethral patency rate respectively 66.6% 100%. poorer results acellular bladder matrix apparent cases unhealthy urethral bed . several small retrospective case series using mainly porcine small intestinal submucosa, demonstrate varying patency rates 20-110%. patient groups heterogenious terms aetiology, previous treatment, urethral location definition success rate. overview found table 9.3. papers report poorer outcome case extensive spongiofibrosis, poor vascular graft bed, previous treatments longer strictures [531-535] (table 9.3). table 9.3: outcome retrospective case series using cell-free tissue engineered grafts studynfu (mo)type graftpatency rate (%)el-kassaby et al. 2008 1525cadaveric acellular bladder matrix33-88palminteri et al. 2012 3071porcine small intestinal submucosa76xu et al. 2013 2824.8porcine small intestinal submucosa92tang et al. 2020 4915allogeneic acellular dermal matrix85.7fiala et al. 2007 5031.2porcine small intestinal submucosa80 summary evidencelepatency rate cell-free tissue engineered grafts decreases large stricture length unhealthy urethral bed.1b recommendationstrength ratingdo use cell-free tissue engineered grafts case extensive spongiofibrosis, failed previous urethroplasty stricture length > 4 cm.weak 9.4.2. autologous tissue engineered oral mucosa graftss grafts contain matrix seeded autologous oral mucosa cells. production requires small oral mucosa biopsy (at 0.5 cmÂ²) graft manufactured lab. main advantage suggested reduction oral donor site morbidity whereas main disadvantages costs strict time frame manufacturing implantation graft . clinical use autologous tissue-engineered omg evaluated prospective, multicentre study including 99 patients . estimated twelve- 24-months urethral patency rate 67.3 58.2%, respectively. oral adverse events minimal. comparative studies acellular grafts native omgs available data cost-effectiveness . summary evidencelesafety, patency rate cost-effectiveness autologous tissue-engineered grafts currently research.3 recommendationstrength ratingdo use autologous tissue-engineered oral mucosa grafts outside frame clinical trial.strong